Morgan Stanley Downgrades IMS Health (RX) to Underweight
More News related to RX
- BioSyent Releases 2009 Third Quarter Financial Results
- BioSyent Releases 2009 Third Quarter Financial Results
- Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low
- IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies
- Law Offices of Brian M. Felgoise, P.C. Announces Investigation on Behalf of Shareholders of IMS Health, Inc.
More News related to Downgrades
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Morgan Stanley downgrades IMS Health (NYSE: RX) from Equalweight to Underweight. Price target $18.
IMS Health Incorporated (IMS) is a provider of market intelligence to the pharmaceutical and healthcare industries.
Related Categories
DowngradesStocks Mentioned
-0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
